首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Enfortumab ELISA Kit (KPTX272)

概述
图片
参考文献

概述

货号	KPTX272
品牌	ProteoGenix
描述	Enfortumab ELISA Kit (KPTX272) — Quantitative colorimetric ELISA. for Enfortumab. Sample: Plasma, Serum. Range: 93.75 - 1,500 ng/mL. Highlights High Sensitivity — Reliable quantification at low concentrations. Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型	Plasma, Serum
检测范围	93.75 - 1,500 ng/mL
保存溶液	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
检测方法	Colorimetric
实验类型	Quantitative
回收率	80-120%
运输	2-8 ℃
规格	Enfortumab
别名	AGS-22CE, AGS-22M, AGS-22M6E, unconjugated : AGS-22C3 or AGSM6, CAS: 1346452-25-2
背景	Enfortumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of cancer expressing Nectin-4. It was developed through two main lines, hybridoma (ASG-22ME) and Chinese hamster ovary (ASG-22CE). Enfortumab refers to the fully humanized (from mouse) monoclonal antibody (mAb) created by scientists at Agensys (part of Astellas) using Amgen’s transgenic system (XenoMouse), it is the first agent to target Nectin-4 that expressed on many solid tumors especially on bladder cancers. Vedotin refers to the payload drug microtubule-disrupting agent monomethyl auristatin E (MMAE) and the linker. The linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics. Preclinical studies showed that enfortumab vedotin effectively binds to target cells, internalizes and induces cell-killing activity. Mouse and patient xenograft models were used to test enfortumab vedotin’s antitumor activity in human breast, bladder, pancreatic and lung cancers. In March 2018, Seattle Genetics and Astellas received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for enfortumab vedotin based on interim results from the phase 1 study examining enfortumab vedotin as monotherapy treatment for patients with metastatic urothelial cancer who were previously treated with checkpoint inhibitors.
Note	For Research Use Only.

图片

参考文献

公式

质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)

填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。

质量

=

浓度

×

体积

分子量 *

g/mol

公式

C₁ × V₁ = C₂ × V₂

填写 4 项中的任意 3 项，自动计算未知值。

母液

C₁ (起始浓度)

×

V₁ (起始体积)

=

工作液

C₂ (终浓度)

×

V₂ (终体积)

相关产品推荐

Enfortumab ELISA Kit

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有所有产品仅可用于工业或者科研等非医疗目的。

鄂ICP备2023002448号-2